

CHO-K1/Mouse β3-adrenoceptor Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0030B | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The β3-adrenoceptor is a G-protein-coupled receptor primarily found on the surface of fat cells (adipocytes) and the smooth muscle of the urinary bladder. Its main roles are to stimulate the breakdown of stored fat (lipolysis) to increase energy expenditure and to promote relaxation of the bladder muscle, thereby increasing its capacity. Because of these key functions, the β3-adrenoceptor has become a significant therapeutic target, with agonists like mirabegron being successfully used to treat overactive bladder syndrome and others under investigation for their potential to combat metabolic disorders like obesity and type 2 diabetes.
Screeningbio’s CHO-K1/Mouse β3-adrenoceptor cell line overexpress Mouse ADRB3 and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Mouse |
HGNC Symbol | β3-adrenoceptor |
Accession Number | NM_013462 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![CHO-K1/Mouse β3-adrenoceptor Agonist Assay. CHO-K1/Mouse β3-adrenoceptor cells were treated with the reference agonist L-Adrenaline. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_0cd9de6f92184fcc8f2b57b3be1d4f88~mv2.png/v1/fill/w_75,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_0cd9de6f92184fcc8f2b57b3be1d4f88~mv2.png)
Target Background
The β3-adrenoceptor is a G-protein-coupled receptor primarily found on the surface of fat cells (adipocytes) and the smooth muscle of the urinary bladder. Its main roles are to stimulate the breakdown of stored fat (lipolysis) to increase energy expenditure and to promote relaxation of the bladder muscle, thereby increasing its capacity.
Because of these key functions, the β3-adrenoceptor has become a significant therapeutic target, with agonists like mirabegron being successfully used to treat overactive bladder syndrome and others under investigation for their potential to combat metabolic disorders like obesity and type 2 diabetes.